News | June 09, 2024
Gavi outlines plans to support access to new vaccines
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
This strategic decision will unlock significant value for our scientific and industrial products business
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Subscribe To Our Newsletter & Stay Updated
